GlaxoSmithKline Pharmaceuticals Limited

2.5 billion

hat. Now, clearly, as we look at that, what we also want to do through that is to impact around 2.5 billion patients in the next 10 years and positively impact them through our portfolio. Now, where are th

2.5 billion

mean, you can’t think about it, you can’t take out India out of that equation, when we talk about 2.5 billion patients, some bit of rough calculations that we have done suggest around 60% of the 2.5 billion

60%

talk about 2.5 billion patients, some bit of rough calculations that we have done suggest around 60% of the 2.5 billion will be out of India. So a huge part, I can say, of the global GSK purpose,

17%

ortfolio. We also contribute greatly to many of our key brands that we have. Augmentin, there are 17% of the emerging markets flow, Derma we are on 45-50% of emerging markets, clearly a huge portfoli

50%

ey brands that we have. Augmentin, there are 17% of the emerging markets flow, Derma we are on 45-50% of emerging markets, clearly a huge portfolio. And we clearly feel that in India, we still have a

25 million

is something we are extremely excited about. As we speak today, there is a cohort of around 24 to 25 million per year. I mean, the birth cohort in India is 24 to 25 million. And if you see one of the most p

1 million

of the most penetrated paediatric vaccine in this country is a pneumococcal vaccine which gets to 1 million kids. And I’m not talking about the National Immunization [Policy] vaccine, so don’t get me wro

85%

[Policy] vaccine, so don’t get me wrong. So, the National Immunization vaccine gets you around 80-85%... So forget and I’m not talking about that, but I’m talking about those vaccines, which are outs

rs,

oing on the business front. I’ll hand it over to Juby who will quickly walk you through some numbers, facts and figures. And, as I promised, we will be done in the next 8-10 minutes and then we’ll o

3,190 crore

the last couple of years. So firstly, this is a quick snapshot of 2022. If you see, our sales is 3,190 crores and 11 percent growth. Now what’s really important is price as well as the volume - both are gro

19%

ms of growth. General medicines, which form part of the entire pharmaceutical brands is growing 19%. Speciality - which includes Nucala and all the new assets where we are getting new products laun

86%

includes Nucala and all the new assets where we are getting new products launched -that’s growing 86% almost doubling last year. Vaccines saw a decline of 9 percent. Again vaccines as you know, durin